357 related articles for article (PubMed ID: 26202204)
21. Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma.
Venkatesan N; Kanwar JR; Deepa PR; Navaneethakrishnan S; Joseph C; Krishnakumar S
Chem Biol Interact; 2016 May; 252():141-9. PubMed ID: 27062892
[TBL] [Abstract][Full Text] [Related]
22. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
24. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
25. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study.
Radhakrishnan V; Kumar R; Malhotra A; Bakhshi S
J Nucl Med; 2012 Feb; 53(2):191-8. PubMed ID: 22251556
[TBL] [Abstract][Full Text] [Related]
26. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
27. Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor.
Yang W; Jiang XX; Zhao XY; Mao PA
Kaohsiung J Med Sci; 2022 Mar; 38(3):244-252. PubMed ID: 34741392
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D analogs, a new treatment for retinoblastoma: The first Ellsworth Lecture.
Albert DM; Nickells RW; Gamm DM; Zimbric ML; Schlamp CL; Lindstrom MJ; Audo I
Ophthalmic Genet; 2002 Sep; 23(3):137-56. PubMed ID: 12324873
[TBL] [Abstract][Full Text] [Related]
29. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.
Gobin YP; Dunkel IJ; Marr BP; Brodie SE; Abramson DH
Arch Ophthalmol; 2011 Jun; 129(6):732-7. PubMed ID: 21320950
[TBL] [Abstract][Full Text] [Related]
30. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
31. Hand-held spectral-domain optical coherence tomography of small macular retinoblastoma in infants before and after chemotherapy.
Cao C; Markovitz M; Ferenczy S; Shields CL
J Pediatr Ophthalmol Strabismus; 2014 Jul; 51(4):230-4. PubMed ID: 25922867
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
Millard M; Pathania D; Grande F; Xu S; Neamati N
Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
35. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the therapeutic perspectives of Nutlin-3.
Secchiero P; Bosco R; Celeghini C; Zauli G
Curr Pharm Des; 2011; 17(6):569-77. PubMed ID: 21391907
[TBL] [Abstract][Full Text] [Related]
37. Kinase inhibitors: the road ahead.
Ferguson FM; Gray NS
Nat Rev Drug Discov; 2018 May; 17(5):353-377. PubMed ID: 29545548
[TBL] [Abstract][Full Text] [Related]
38. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
39. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
40. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
Bandaru S; Ponnala D; Lakkaraju C; Bhukya CK; Shaheen U; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(9):3759-65. PubMed ID: 25987034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
